Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

312,859-312,876 of 319,975

filter-aware
11
Uses a 'Yesterday vs Tomorrow' framework to contrast legacy infrastructure challenges with the proposed solution.Elisity Series A Pitch Deck · elisity-series-a-pitch-deck
Pitch deck Investor relations Beat · Market OpportunityLoop · Why Now1 hit
12
The slide uses a before-after comparison of security solutions within a specific enterprise context.Elisity Series A Pitch Deck · elisity-series-a-pitch-deck
Pitch deck Investor relations Beat · Market OpportunityLoop · Why Now1 hit
13
The chart segments companies into Midsized, Large, and Very Large categories.Elisity Series A Pitch Deck · elisity-series-a-pitch-deck
Pitch deck Investor relations Beat · Market OpportunityLoop · Why Now1 hit
14
Elisity Series A Pitch DeckElisity Series A Pitch Deck · elisity-series-a-pitch-deck
Pitch deck Investor relations Loop · Why Now1 hit
15
Uses a 'Before/After' framing to demonstrate value proposition.Elisity Series A Pitch Deck · elisity-series-a-pitch-deck
Pitch deck Investor relations Loop · Why Now1 hit
16
Elisity Series A Pitch DeckElisity Series A Pitch Deck · elisity-series-a-pitch-deck
Pitch deck Investor relations Loop · Why Now1 hit
17
Elisity Series A Pitch DeckElisity Series A Pitch Deck · elisity-series-a-pitch-deck
Pitch deck Investor relations 1 hit
01
Slide 1
This is a formal investor letter from Elliott Advisors to GSK.Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst 1 hit
02
The table shows cumulative total return comparison in percentages across various time horizons (1-10 years) against a peer group of pharmaceutical companies.Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
03
The slide serves as a summary of the investment rationale, referencing detailed appendices for specific business units and valuation.Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
04
Elliott Management GSK Letter July 2021Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
05
Page number 5 indicates this is part of a larger document.Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
06
The slide highlights a 'credibility gap' and proposes leadership changes as a path forward.Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
07
This slide outlines Elliott's strategic recommendations for GSK's governance and performance management.Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
08
Page 8 of an investor presentation, likely from Elliott Management.Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
09
This is a formal letter page rather than a traditional presentation slide, serving as the concluding section of an activist investor proposal.Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
10
Elliott Management GSK Letter July 2021Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst Beat · Evidence & Proof1 hit
11
Includes two bar charts: 2021-2026 revenue CAGR and 2027-2030 revenue change with LOE years.Elliott Management GSK Letter July 2021 · elliott-management-gsk-letter-july-2021
Document Independent analyst Beat · Evidence & Proof1 hit